See today's BioWorld
To read the full story, subscribe or sign in.

Henlius licenses adalimumab biosimilar to Pakistan’s Getz Pharma for $8M

Feb. 28, 2022
By Doris Yu
Shanghai Henlius Biotech Inc. has licensed its adalimumab biosimilar Handayuan to Getz Pharma Pvt. Ltd. and its affiliated company Getz Pharma International FZ LLC in an $8 million deal.
BioWorld Deals and M&A Biosimilar Asia-Pacific China